Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia

Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia

Abstract Background 5-α reductase inhibitors (5-ARIs) are first-line drugs for managing benign prostatic hyperplasia (BPH). Unfortunately, some patients do not respond to 5-ARI therapy and may even show worsening symptoms. The decreased expression of steroid 5-α reductase type 2(SRD5A2) in BPH tissu...

Full description

Bibliographic Details
Main Authors: Zhanliang Liu, Zhemin Lin, Fang Cao, Mingxin Jiang, Song jin, Yun Cui, YN Niu
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Urology
Subjects:
5-α reductase
Benign prostatic hyperplasia
miR-1199-5p
Online Access:https://doi.org/10.1186/s12894-022-01121-5

Internet

https://doi.org/10.1186/s12894-022-01121-5

Similar Items